Sequential adjuvant chemotherapy for patients with high-risk urinary tract carcinomas: A retrospective analysis of a patient's series

Fable Zustovich, Patrizia Farina, Nabil Amirouchene, Paolo Carli, Giovanni Rosti, Giuseppe Lombardi, Giuseppe Cartei

Research output: Contribution to journalArticlepeer-review

Abstract

Aims and Background: there is no evidence of benefit for adjuvant chemotherapy in high-risk patients with urothelial carcinomas; to improve results of surgery we treated a series of patients with a multi-drug sequential chemotherapy protocol. Methods: patients with G3 or pT3 or pN+ urinary tract carcinomas were treated with 3 courses of carboplatin plus gemcitabine every 21 days followed by 3 courses of paclitaxel, vinorelbine and methotrexate every 21 days. Results: 21 patients were enrolled, all patients were evaluable for toxicity that was manageable and mostly haematological grade 1-2, 9 patients needed some dose reduction. The median disease-free survival (DFS) was of 21.8 months (4.3-48.7+) and median overall survival (OS) was of 25.4 months (9-51.4). Conclusions: carboplatin and gemcitabine followed by paclitaxel, vinorelbine and methotrexate is feasible and safe and might deserve to be studied in a fase III trial of adjuvant chemotherapy for patients with high-risk urothelial carcinomas.

Original languageEnglish
Pages (from-to)51-55
Number of pages5
JournalCancer Therapy
Volume8
Issue numberISSUE A
Publication statusPublished - 2010

Keywords

  • Adjuvant
  • Bladder
  • Chemotherapy
  • Urothelial

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Sequential adjuvant chemotherapy for patients with high-risk urinary tract carcinomas: A retrospective analysis of a patient's series'. Together they form a unique fingerprint.

Cite this